DARZALEX^® as monotherapy

DARZALEX^® was studied as monotherapy (by itself) in 106 patients who had either received at least 3 prior medicines to treat their multiple myeloma, including a proteasome inhibitor (PI) and an immunomodulatory agent, or did not respond to a PI and an immunomodulatory agent. These patients had received a median of five prior lines of therapy for their multiple myeloma.

The main goal of the study was to measure overall response rate, which is the percentage of patients who responded to treatment.

Clinical study results: DARZALEX^® as monotherapy

When these patients were treated with DARZALEX^®, 29% responded.

• This response lasted for a median duration of 7.4 months (1.2 to 13.1+ months).